RE: wow!!22 Jan 2021 15:56
Nice write up by share prophets
SkinBioTherapeutics - AxisBiotix study enrolment commences, set for a breakthrough year?...
Versarien needs to restate and reissue interims, they are deceptive. Letter to AIM Regulation from Tom Winnifrith, The Sheriff of AIM, HERE
Making SkinBioTherapeutics (SBTX) one of our three tips of the year 2021, we noted we considered it likely to make 2021 a breakthrough year, including with a planned first quarter human study for AxisBiotix™ targeting psoriasis and then, subject to a positive readout, commencing commercialisation. Already we now have an “Enrolment for AxisBiotix-PsT study commences” announcement and the shares are already massively higher than our 15.5p tip price, but...
Ridgecrest ramp – Sordid LSE Sharetalk & Peterhouse an axis of evil? Read HERE
The study is a food supplement consumer study – it following partner Dutch company Winclove having completed formulation and manufacture of the supplement with a blend of bacterial strains to balance the gut microbiome to address the overproduction of new skin cells often seen in aggressive skin conditions such as psoriasis. The study is to accept approximately 200 applicants and will run for 56 days. There should be quick progress from here – it noted the supplements are currently being packaged ahead of shipment to the company in early February, an expected study start date before the end of February and expected reporting of findings “shortly” after the study with, subject to a positive outcome, a commercial launch and initiation of a clinic-based study looking at specific markers also this year.
Gold: The View from the Montana Log-Cabin as Bull (Jordan Roy-Byrne) takes on Bull (Ross Norman). From Nigel Somerville HERE
It should be helped by, and the opportunity is with, approximately 2% of the global population believed to suffer from psoriasis and current therapies tend to be steroid-based, which cannot be used long term and have side effects. Thus this opportunity could be bigger than that of company’s deal with FTSE-100 Croda for its SkinBiotix® technology as a cosmetic ingredient – we noting on the tip of the year that alone could generate annual profits of £25 million per annum, with also the company now cashed-up and also other potential deals we expect to be announced this year.
Iconic Labs – how big is the EGHOS debt dispute and why was OTT Holdings kept in the dark? Read HERE
The market cap is still below £50 million and the noted potential suggests still multi-bagger prospects from here. Tom Winnifrith owns the shares and our target price here now is 45p
Sign In
Follow the stocks
